Live
- MUDA scam: Petitioner urges Lokayukta to probe documents taken away by minister to help Siddaramaiah
- Maharashtra: Tribal residents of Yavatmal realise their dream of 'pucca' house under PMAY
- FIIs to reduce selling in India towards year-end, fresh allocations to occur
- ESPN Tests AI Avatar' FACTS' for Sports Analytics
- Amit Shah accuses Hemant Soren of shielding Bangladeshi infiltrators
- I’m a fool essentially providing free funding to OpenAI: Musk once told Altman
- Have plans A, B, C and D in hand as there’s no certainty in the player auction, says RCB's Bobat
- ISRO to launch communication satellite aboard Elon Musk’s SpaceX rocket
- Congress opens shop of lies & loot during elections: Rajasthan CM
- Indian startups raise over $182 million in funding this week
Suven gets patent for neurological molecule
Suven Life Sciences has received a patent approval by Singapore corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases.
Hyderabad: Suven Life Sciences has received a patent approval by Singapore corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases.
According to a company’s communique to BSE, “the patent is valid till 2033. Venkat Jasti, CEO, Suven Life, said: “We’re very pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS arena, which are being developed for cognitive disorders with high unmet medical need with a huge market potential globally.”
The granted claims of the patent are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimers disease, attention deficient hyperactivity disorder (ADHD), Huntingtons disease, Parkinsons and Schizophrenia. Suven Life Sciences shares closed higher by Rs1.90 or 0.86 percent at Rs223.35 on BSE.
